The analogue of sphingosine, FTY720 (Fingolimod), is an Food and Drug Administration (FDA)-approved immunomodulator and has been shown effective in vitro and in vivo cancer models through functional antagonism of S1PR1 and inhibition Sphk1 [24], suggesting a potential therapeutic role in cancer patients. Here, S1PR1 is linked to cancer.